J
Jialiang Brain Science
Neurosurgical medical devices for treating neurological disorders.
About Jialiang Brain Science
Genlight MedTech, also referred to as Jialiang Brain Science, is a medical device company established in 2020 and headquartered in Hangzhou, China. The firm focuses on developing and industrializing technologies for neurosurgery and brain science. Its research and development are concentrated on creating solutions for neurological conditions such as drug-refractory epilepsy, brain tumors, Parkinson's disease, and depression.
The company's product portfolio is built on several advanced technology platforms, including brain-computer interfaces, medical lasers, and brain-computer chips. Key products include LaserRO, an MRI-guided laser ablation (LITT) minimally invasive surgical system, and BCmod, a closed-loop neuromodulation technology platform for central nervous system diseases. They also provide neurosurgical robots and scientific research services based on neurocognition. Two of its products have received breakthrough device designation from the NMPA, China's medical products regulator.
Since its founding, Genlight has achieved several milestones, including securing Pre-Series A and Series B+ funding, the acquisition of Hangzhou Nuowei Medical in 2021, and being named a "Hangzhou Future Unicorn" in 2023. The company actively collaborates with academic institutions, such as establishing a joint research and development center with Zhejiang University of Technology. As of 2023, Genlight employed approximately 170 people and held over 160 patents.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Hangzhou, China
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 53.4/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Neurology, Neuromodulation and Neurostimulation, Brain Computer Interfaces
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Sep 2026 | — | — | Xiaomiao Langcheng · Saizhibole · Nanjing Jiangbei State-owned Assets | ↗ |
| SERIES C✓Equity / VC | May 2026 | $28M | $825M | CD Capital · Yufu Holdings · Yuhang Financial Holdings · Hangzhou Hi-Tech Financial Investment Group | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later10 investors entered at this stage
CD Capital- YHYufu Holdings
- YHYuhang Financial Holdings
- HGHangzhou Hi-Tech Financial Investment Group
- PCPUXIN Capital
- TITailong Investment
Southwest Securities- XLXiaomiao Langcheng
- SASaizhibole
- NANanjing Jiangbei State-owned Assets
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jialiang Brain Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jialiang Brain Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






